Институт стволовых клеток человека logo
Институт стволовых клеток человека ISKJ

Институт стволовых клеток человека Financial Statements 2006-2026 | ISKJ

Key Metrics Институт стволовых клеток человека

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006

Operating Cash Flow Per Share

4.69 2.53 3.51 0.718 2.34 0.259 -0.262 0.481 0.061 0.51 1.1 -0.355 0.589 0.002 0.731 0.498 0.082 -

Free Cash Flow Per Share

2.48 0.971 1.59 -0.423 -0.274 -0.212 -3.1 -0.412 -0.196 0.072 0.64 -1.02 0.163 -0.141 0.549 0.187 -0.041 -

Cash Per Share

6.17 3.25 2.73 1.7 2.54 2.73 1.72 5.04 2.8 2.77 1.47 0.356 0.243 1.17 2.57 0.07 0.087 -

Price To Sales Ratio

5.23 5.89 7.78 2.64 1.17 0.926 1.74 3.47 2.52 2.3 3.48 3.22 3.17 4.01 5.94 9.17 13.6 -

Dividend Yield

- - - - - - - 0.016 - - - - - 0.01 0.01 0.004 - -

Payout Ratio

- - - - - - - -0.191 - - - - - 1.12 0.194 0.497 - -

Revenue Per Share

14.8 13.1 14.8 14.5 11.1 8.6 6.59 5.2 4.14 4.79 5.6 4.22 3.67 3.21 2.44 1.58 1.06 -

Net Income Per Share

1.82 0.531 0.419 1.38 1.13 -0.456 -1.37 -1.48 -0.687 -0.176 0.196 -2 0.256 0.112 0.737 0.11 0.1 -

Book Value Per Share

10.5 6.56 5.76 5.53 4.94 1.62 1.71 3.18 4.79 5.63 4.83 8.94 11.4 3.24 3.25 0.281 0.227 -

Tangible Book Value Per Share

8.62 -1.92 -1.03 -0.587 -0.655 -2.6 0.276 2.39 4.16 4.95 4.34 8.28 11 3.19 3.23 0.259 0.225 -

Shareholders Equity Per Share

5.39 3.92 2.93 2.59 1.32 0.36 0.683 2.05 3.83 4.52 4.69 8.77 11.3 3.21 3.23 0.258 0.202 -

Interest Debt Per Share

8.48 10.3 8.35 7.05 6.21 5.4 5.93 4.98 1.64 1.48 1.97 2.06 0.152 0.005 0.006 0.053 0.001 -

Market Cap

7.15 B 6.7 B 9.19 B 2.86 B 974 M 597 M 862 M 1.35 B 784 M 825 M 1.46 B 1.02 B 830 M 772 M 870 M 887 M 891 M -

Enterprise Value

7.4 B 7.33 B 9.62 B 3.24 B 1.31 B 907 M 1.17 B 1.41 B 848 M 853 M 1.57 B 1.14 B 823 M 702 M 716 M 886 M 886 M -1.63 M

P/E Ratio

42.4 145 274 27.7 11.5 -17.5 -8.41 -12.2 -15.2 -62.5 99.1 -6.8 45.4 115 19.6 132 145 -

P/OCF Ratio

16.5 30.4 32.7 53.1 5.55 30.7 -43.9 37.6 170 21.6 17.7 -38.3 19.7 6.71 K 19.8 29.1 177 -

P/FCF Ratio

31 79.4 72.1 -90.2 -47.5 -37.5 -3.71 -43.8 -53.3 154 30.4 -13.3 71.1 -91.3 26.4 77.5 -357 -

P/B Ratio

14.3 19.6 39.2 14.7 9.87 22.1 16.8 8.8 2.72 2.43 4.15 1.55 1.03 4 4.49 56.2 71.8 -

EV/Sales

5.4 6.45 8.14 2.99 1.57 1.41 2.37 3.62 2.73 2.37 3.74 3.61 3.14 3.65 4.89 9.16 13.5 -

EV/EBITDA

22.7 48.7 59.6 15.6 6.45 7.09 -432 -14.3 -14.4 23 24.4 105 32 44.6 13.3 80.5 99.6 -

EV/OCF

17 33.3 34.2 60.2 7.45 46.7 -59.5 39.2 184 22.3 19 -42.9 19.5 6.11 K 16.3 29 176 -

Earnings Yield

0.024 0.007 0.004 0.036 0.087 -0.057 -0.119 -0.082 -0.066 -0.016 0.01 -0.147 0.022 0.009 0.051 0.008 0.007 -

Free Cash Flow Yield

0.032 0.013 0.014 -0.011 -0.021 -0.027 -0.27 -0.023 -0.019 0.007 0.033 -0.075 0.014 -0.011 0.038 0.013 -0.003 -

Debt To Equity

1.57 2.44 2.63 2.51 4.3 13.9 8.09 2.25 0.399 0.292 0.367 0.227 0.013 0.0 0.0 0.191 - -

Debt To Assets

0.309 0.407 0.355 0.323 0.303 0.333 0.393 0.333 0.138 0.123 0.177 0.149 0.011 0.0 0.0 0.046 - -

Net Debt To EBITDA

0.743 4.18 2.63 1.83 1.65 2.42 -113 -0.615 -1.09 0.755 1.72 11.3 -0.269 -4.44 -2.87 -0.119 -0.599 -

Current Ratio

1.99 1.74 1.77 1.04 1.05 1.15 0.705 1.18 0.863 0.895 0.662 0.817 1.02 1.47 2.41 0.409 1 0.951

Interest Coverage

- 1.64 1.82 3.66 4.34 3.88 -1.89 -5.31 -11 -4.29 2.31 -2.17 40.2 23.5 77 28.9 183 -

Income Quality

2.58 9.55 8.37 0.521 1.58 -1.06 0.179 -0.275 -0.074 -2.3 4.95 0.187 2.19 0.012 0.878 3.56 0.626 -

Sales General And Administrative To Revenue

0.047 0.028 0.027 0.024 0.049 0.04 0.045 0.168 0.113 0.13 0.047 0.033 0.03 0.052 0.061 0.097 0.127 -

Intangibles To Total Assets

0.069 0.36 0.312 0.304 0.3 0.281 0.102 0.057 0.057 0.063 0.051 0.049 0.029 0.01 0.006 0.021 0.003 0.006

Capex To Operating Cash Flow

0.47 0.617 0.546 1.59 1.12 1.82 -10.8 1.86 4.2 0.859 0.418 -1.89 0.723 74.5 0.25 0.625 1.5 -

Capex To Revenue

0.149 0.12 0.13 0.079 0.235 0.055 0.43 0.171 0.062 0.091 0.082 0.159 0.116 0.045 0.075 0.197 0.115 -

Capex To Depreciation

2.88 2.54 1.89 1.14 3.27 1.19 5.26 2.79 0.737 1.31 1.53 5.59 5.02 1.72 3.08 8.59 9.25 -

Stock Based Compensation To Revenue

0.001 - - - - - - - - - - - - - - - - -

Graham Number

14.9 6.84 5.26 8.96 5.78 1.92 4.58 8.28 7.7 4.23 4.55 19.9 8.07 2.85 7.32 0.799 0.674 -

Return On Invested Capital, ROIC

0.114 0.049 0.077 0.142 0.187 0.052 -0.092 -0.209 -0.197 9.86 0.053 -0.014 0.02 0.025 0.124 0.238 0.392 -

Return On Tangible Assets, ROTA

0.071 0.035 0.028 0.098 0.086 -0.042 -0.109 -0.114 -0.066 -0.017 0.021 -0.157 0.019 0.023 0.163 0.105 0.167 -

Graham Net Net

-8.86 -12.4 -11.7 -11.4 -10 -9.72 -9.79 -5.21 -3.16 -2.01 -3.32 -3.71 -1.94 -0.428 1.32 -0.69 -0.27 -

Working Capital

556 M 294 M 286 M 19.8 M 22.2 M 61 M -165 M 84.5 M -57.5 M -38.4 M -110 M -37.1 M 2.13 M 47.3 M 109 M -28.4 M 93 K -657 K

Tangible Asset Value

800 M -166 M -82.1 M -44 M -49.1 M -195 M 20.7 M 179 M 312 M 371 M 325 M 621 M 789 M 191 M 194 M 15.9 M 13.8 M 6.14 M

Net Current Asset Value, NCAV

-452 M -785 M -619 M -521 M -519 M -529 M -531 M -239 M -112 M -56.9 M -150 M -166 M -59.5 M 46.6 M 109 M -28.4 M 92 K -659 K

Invested Capital

1.05 B 1.31 B 1.11 B 809 M 821 M 654 M 226 M 297 M 86.8 M 123 M 44.1 M 78.6 M 68 M 85.9 M 144 M -826 K 10.7 M 3.2 M

Average Receivables

40.9 M - - - - - - - - - 12.8 M 12.8 M - - - - - -

Average Payables

60.1 M 84.6 M 99.8 M 90 M 102 M 97.1 M 80.2 M 53.5 M 14.3 M 12.7 M 15.6 M 21.1 M 16.7 M 8.62 M 26.9 M 32.3 M 17.6 M -

Average Inventory

225 M 235 M 240 M 203 M 155 M 131 M 94 M 58.1 M 51.5 M 33 M 16 M 15.8 M 12.2 M 6.6 M 3.25 M 2.51 M 1.65 M -

Days Sales Outstanding

21.8 - - - - - - - - - - 29.4 - - - - - -

Days Payables Outstanding

48.4 93.9 129 115 184 558 287 476 149 115 358 166 347 943 820 8.02 K 19.2 K -

Days Of Inventory On Hand

205 315 310 275 384 633 489 348 401 631 335 187 189 1.45 K 270 537 1.89 K -

Receivables Turnover

16.7 - - - - - - - - - - 12.4 - - - - - -

Payables Turnover

7.53 3.89 2.83 3.19 1.99 0.655 1.27 0.767 2.46 3.17 1.02 2.2 1.05 0.387 0.445 0.045 0.019 -

Inventory Turnover

1.78 1.16 1.18 1.33 0.952 0.577 0.746 1.05 0.91 0.578 1.09 1.95 1.93 0.251 1.35 0.679 0.193 -

Return On Equity, ROE

0.337 0.135 0.143 0.532 0.856 -1.27 -2 -0.724 -0.179 -0.039 0.042 -0.228 0.023 0.035 0.228 0.427 0.496 -

Capex Per Share

2.2 1.56 1.92 1.14 2.62 0.471 2.84 0.892 0.257 0.438 0.46 0.67 0.426 0.143 0.183 0.311 0.122 -

All numbers in RUB currency

Quarterly Key Metrics Институт стволовых клеток человека

2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q3

Operating Cash Flow Per Share

0.001 0.001 0.003 0.003 0.0 0.0 0.001 0.001 0.0 0.0 2.71 0.001 0.51 0.0 - 0.001 - -0.0 - 0.001 0.0 0.0 -0.0 -0.0 0.001 0.001 0.54 -0.173 -0.0 -0.0 1.88 -1.11 - -0.316 0.0 0.0 -0.0 -0.0 -0.0 - 0.0 - 0.0 - - - -

Free Cash Flow Per Share

0.0 0.0 0.002 0.002 -0.0 -0.0 0.001 0.001 -0.0 -0.0 0.763 0.001 -0.225 -0.0 - 0.001 - -0.001 - -0.0 0.0 0.0 -0.0 -0.0 -0.0 -0.0 0.323 -0.854 -0.002 -0.001 1.2 -1.2 - -0.316 0.0 0.0 -0.0 -0.0 -0.0 - 0.0 - 0.0 - - - -

Cash Per Share

0.005 0.005 0.008 0.008 0.005 0.005 0.003 0.003 0.001 0.001 0.003 0.002 0.001 0.001 0.002 0.001 0.003 0.002 2.54 0.002 0.002 0.002 0.003 0.003 0.003 0.003 1.72 2.66 0.004 0.006 5.04 4.75 - 2.39 0.003 0.003 0.003 0.002 0.002 0.002 0.003 2.62 0.001 0.001 - 1.16 -

Price To Sales Ratio

15.3 K 15.3 K 15.5 K 15.5 K 18.4 K 18.4 K 22.2 K 22.2 K 25.6 K 29.6 K 13.5 25.1 K 5.01 10.1 K 4.99 8.13 K 2.98 3.87 K 0.002 4.94 K 3.49 K 3.6 K 3.4 K 3.93 K 4.86 K 4.63 K 6.07 7.84 8.04 9.39 12.9 16.6 - 21.3 9.87 9.68 9.23 K 9.18 K 8.91 9.91 12.2 K 10.9 14.3 K 13.2 K - 8.59 -

Dividend Yield

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Payout Ratio

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue Per Share

0.005 0.005 0.005 0.005 0.004 0.004 0.003 0.003 0.003 0.003 8.5 0.004 7.64 0.004 7.64 0.004 8.66 0.003 6.04 K 0.003 0.003 0.003 0.002 0.002 0.002 0.002 1.9 1.67 1.49 1.53 1.4 1.1 - 1.25 1.06 1.06 0.001 0.001 1.23 1.23 0.001 1.41 0.001 0.001 - 1.61 -

Net Income Per Share

0.001 0.001 0.001 0.001 0.0 0.0 0.0 0.0 0.0 0.0 0.147 -0.0 0.384 0.0 0.384 0.0 0.158 0.0 1.23 K 0.0 0.0 0.0 -0.0 -0.0 0.0 0.0 -1.11 0.331 -0.0 -0.0 -0.084 -0.557 - -0.097 -0.0 -0.0 0.0 0.0 -0.0 -0.0 0.0 0.721 -0.0 -0.0 - 0.281 -

Book Value Per Share

0.013 0.013 0.013 0.013 0.011 0.011 0.006 0.006 0.006 0.006 0.006 0.005 0.006 0.006 0.006 0.006 0.007 0.007 4.94 0.005 0.003 0.003 0.002 0.002 0.003 0.003 1.71 2.77 0.002 0.003 3.18 3.34 - 4.7 0.005 0.005 0.006 0.006 0.006 0.006 0.006 10.8 0.005 0.011 - 9.8 -

Tangible Book Value Per Share

0.011 0.011 0.011 0.011 0.001 0.009 -0.002 0.005 -0.001 0.004 -0.001 0.004 -0.001 0.004 -0.001 0.004 0.0 0.005 -0.655 0.003 -0.003 0.001 -0.003 -0.0 -0.002 -0.0 0.276 1.79 0.002 0.002 2.39 3.04 - 4.08 0.004 0.005 0.005 0.006 0.005 0.005 0.005 10.7 0.005 0.01 - 9.49 -

Shareholders Equity Per Share

0.006 0.006 0.007 0.007 0.005 0.005 0.004 0.004 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 1.32 0.001 0.002 0.002 0.0 0.0 0.002 0.002 0.683 1.79 0.001 0.002 2.05 2.13 - 3.74 0.004 0.004 0.005 0.005 0.005 0.005 0.006 10.8 0.005 0.011 - 9.8 -

Interest Debt Per Share

0.011 0.011 0.01 0.01 0.011 0.011 0.009 0.009 0.007 0.007 0.494 0.007 0.392 0.006 0.392 0.007 0.474 0.007 222 0.006 0.007 0.007 0.005 0.005 0.005 0.005 5.63 5.71 0.006 0.006 4.84 5.23 - 1.59 0.002 0.002 0.002 0.002 0.001 0.001 0.002 1.62 0.002 0.002 - 2.12 -

Market Cap

5.7 T 5.7 T 5.8 T 5.8 T 5.72 T 5.72 T 6.85 T 6.85 T 6.65 T 7.69 T 8.43 T 7.82 T 2.79 T 2.8 T 2.78 T 2.56 T 1.88 T 876 B 974 M 1.11 T 672 B 694 B 597 B 690 B 713 B 679 B 862 M 982 M 900 B 1.08 T 1.35 B 1.37 B - 1.99 B 784 B 769 B 701 B 698 B 825 B 917 B 1.07 T 1.16 B 1.46 T 1.34 T - 1.04 B -

Enterprise Value

5.7 T 5.7 T 5.8 T 5.8 T 5.72 T 5.72 T 6.85 T 6.85 T 6.65 T 7.69 T 8.43 T 7.82 T 2.79 T 2.8 T 2.78 T 2.56 T 1.88 T 876 B 1.31 B 1.11 T 672 B 694 B 597 B 690 B 713 B 679 B 1.17 B 1.29 B 900 B 1.08 T 1.41 B 1.48 B 52 M 2.08 B 784 B 769 B 701 B 698 B 825 B 917 B 1.07 T 1.22 B 1.46 T 1.34 T 111 M 1.19 B 85.8 M

P/E Ratio

34.3 K 34.3 K 21.2 K 21.2 K 89.8 K 89.8 K 162 K 162 K 133 K 154 K 196 -484 K 24.9 71.1 K 24.8 3.07 M 40.9 6.05 K 0.003 16.8 K 6.54 K 6.76 K -4.43 K -5.12 K 10.7 K 10.2 K -2.59 9.9 -9.21 K -13.6 K -53.8 -8.22 - -68.5 -5.77 K -5.66 K 21.4 K 21.3 K -8.85 K -9.84 K 15.9 K 5.34 -28 K -25.7 K - 12.3 -

P/OCF Ratio

101 K 101 K 30.4 K 30.4 K 218 K 218 K 79.2 K 79.2 K 281 K 325 K 42.4 68.8 K 75.1 105 K - 41.5 K - -25.1 K - 14.6 K 44.2 K 45.7 K -19.5 K -22.6 K 17.7 K 16.9 K 21.3 -75.8 -45.3 K -39.5 K 9.6 -16.5 - -84.1 31.6 K 31 K -31.2 K -31 K -58.7 K - 32.1 K - 194 K - - - -

P/FCF Ratio

210 K 210 K 47.7 K 47.7 K -877 K -877 K 102 K 102 K -266 K -307 K 151 122 K -170 -26.6 M - 59 K - -14.8 K - -173 K 60.2 K 62.1 K -210 K -243 K -139 K -133 K 35.6 -15.3 -6 K -25.3 K 15.1 -15.3 - -84.1 42.3 K 41.5 K -27.1 K -27 K -32 K - 37.4 K - 87.1 K - - - -

P/B Ratio

13.2 K 13.2 K 11.6 K 11.6 K 15 K 15 K 20.1 K 20.1 K 24.1 K 27.8 K 35.9 K 33.3 K 12.5 K 12.6 K 14.3 K 13.2 K 8.7 K 4.05 K 9.87 10 K 4.37 K 4.52 K 22.1 K 25.5 K 6.13 K 5.84 K 16.8 7.31 8.22 K 8.06 K 8.8 8.57 - 7.1 2.72 K 2.67 K 1.97 K 1.96 K 2.43 K 2.7 K 2.38 K 1.43 4.15 K 1.7 K - 1.41 -

EV/Sales

15.3 K 15.3 K 15.5 K 15.5 K 18.4 K 18.4 K 22.2 K 22.2 K 25.6 K 29.6 K 13.5 25.1 K 5.01 10.1 K 4.99 8.13 K 2.98 3.87 K 0.003 4.94 K 3.49 K 3.61 K 3.4 K 3.93 K 4.86 K 4.63 K 8.23 10.3 8.04 9.39 13.5 17.9 0.477 22.2 9.87 9.68 9.23 K 9.18 K 8.91 9.91 12.2 K 11.6 14.3 K 13.2 K - 9.83 -

EV/EBITDA

59.4 K 59.4 K 60.4 K 60.4 K 85 K 85 K 207 K 207 K 165 K 191 K 117 161 K 34.8 61.1 K 63.9 57.9 K 52 10.8 K 0.017 17.3 K 14.1 K 14.6 K 9.56 K 11 K 66.3 K 63.2 K -21.1 39.6 -49.2 K -39.4 K 415 -29.9 -0.884 -448 -24.4 K -23.9 K -194 K -193 K -72 K -80 K -1.11 M 16.5 173 K 159 K - 37.1 -

EV/OCF

101 K 101 K 30.4 K 30.4 K 218 K 218 K 79.2 K 79.2 K 281 K 325 K 42.4 68.8 K 75.1 105 K - 41.5 K - -25.1 K - 14.6 K 44.3 K 45.7 K -19.6 K -22.6 K 17.7 K 16.9 K 28.9 -99.9 -45.3 K -39.5 K 10 -17.8 29.1 -87.8 31.6 K 31 K -31.2 K -31 K -58.7 K - 32.1 K - 194 K - - - -

Earnings Yield

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.001 -0.0 0.01 0.0 0.01 0.0 0.006 0.0 94.7 0.0 0.0 0.0 -0.0 -0.0 0.0 0.0 -0.096 0.025 -0.0 -0.0 -0.005 -0.03 - -0.004 -0.0 -0.0 0.0 0.0 -0.0 -0.0 0.0 0.047 -0.0 -0.0 - 0.02 -

Free Cash Flow Yield

0.0 0.0 0.0 0.0 -0.0 -0.0 0.0 0.0 -0.0 -0.0 0.007 0.0 -0.006 -0.0 - 0.0 - -0.0 - -0.0 0.0 0.0 -0.0 -0.0 -0.0 -0.0 0.028 -0.065 -0.0 -0.0 0.066 -0.066 - -0.012 0.0 0.0 -0.0 -0.0 -0.0 - 0.0 - 0.0 - - - -

Debt To Equity

1.82 1.82 1.57 1.57 2.13 2.13 2.44 2.44 2.25 2.25 2.63 2.63 2.14 2.14 2.51 2.51 2.41 2.41 4.3 3.83 3.38 3.38 13.9 13.9 3.47 3.47 8.09 3.13 3.94 3.28 2.25 2.43 0.368 0.413 0.399 0.399 0.329 0.329 0.292 0.292 0.3 0.146 0.367 0.172 0.175 0.21 0.156

Debt To Assets

0.315 0.315 0.309 0.309 0.345 0.345 0.407 0.407 0.356 0.356 0.355 0.355 0.318 0.318 0.323 0.323 0.329 0.329 0.303 0.303 0.364 0.364 0.333 0.333 0.36 0.36 0.393 0.403 0.4 0.393 0.333 0.396 0.099 0.142 0.138 0.138 0.139 0.139 0.123 0.123 0.161 0.098 0.177 0.121 0.124 0.143 0.111

Net Debt To EBITDA

4.37 4.37 2.52 2.52 6.68 6.68 19 19 14 14 0.006 8.73 0.005 9.35 0.009 8.61 0.01 4.48 0.004 5.2 9.69 9.69 4.96 4.96 30.3 30.3 -5.55 9.55 -13.6 -3.85 17.8 -2.18 -0.884 -18.8 -1.99 -1.99 -16.3 -16.3 -2.44 -2.44 -43.1 0.937 13.1 15.4 - 4.69 -

Current Ratio

1.88 1.88 1.99 1.99 2.09 2.09 1.74 1.74 1.98 1.98 1.77 1.77 1.32 1.32 1.04 1.04 1.41 1.41 1.05 1.05 1.22 1.22 1.15 1.15 0.804 0.804 0.705 0.934 0.946 1.27 1.18 1.28 0.699 0.697 0.863 0.863 0.953 0.953 0.895 0.895 0.939 0.852 0.662 0.783 1.05 0.826 0.895

Interest Coverage

- - - - - - - - - - 0.779 - 1.55 - 1.84 - 1.39 - 5.97 - - - - - - - -0.727 0.461 - - -2.33 -21.9 -11.9 1.07 - - - - - - - 0.871 - - - 11.4 -

Income Quality

1.36 1.36 2.79 2.79 1.64 1.64 8.19 8.19 1.89 1.89 -24.6 -28.1 1.88 2.71 - 297 - -0.963 - 4.6 0.592 0.592 0.907 0.907 2.43 2.43 -0.513 -0.515 0.813 1.37 -11.5 1.72 -0.032 3.31 -0.73 -0.73 -2.75 -2.75 0.603 - 1.99 - -0.578 - - - -

Sales General And Administrative To Revenue

0.047 0.047 0.054 0.054 0.039 0.039 0.036 0.036 0.033 0.033 - 0.037 - 0.026 - 0.04 - 0.029 - 0.074 0.05 0.05 0.055 0.055 0.045 0.045 0.023 0.022 0.0 0.0 0.088 0.238 0.142 0.214 0.0 0.0 0.123 0.123 0.0 0.0 0.112 0.23 0.064 0.064 - 0.174 -

Intangibles To Total Assets

0.066 0.066 0.069 0.069 0.316 0.067 0.36 0.073 0.33 0.071 0.312 0.074 0.328 0.078 0.304 0.077 0.285 0.076 0.3 0.091 0.333 0.109 0.281 0.118 0.313 0.207 0.102 0.07 0.063 0.052 0.057 0.023 0.064 0.057 0.057 0.018 0.061 0.025 0.027 0.027 0.053 0.005 0.023 0.015 0.08 0.022 0.021

Capex To Operating Cash Flow

0.519 0.519 0.363 0.363 1.25 1.25 0.223 0.223 2.06 2.06 0.719 0.438 1.44 1 - 0.297 - -0.701 - 1.08 0.265 0.265 -0.907 -0.907 1.13 1.13 0.402 -3.94 -6.55 -0.563 0.363 -0.082 4.98 - 0.253 0.253 -0.151 -0.151 -0.836 - 0.141 - 1.22 - - - -

Capex To Revenue

0.079 0.079 0.186 0.186 0.105 0.105 0.062 0.062 0.187 0.187 0.229 0.16 0.096 0.096 - 0.058 - 0.108 - 0.367 0.021 0.021 0.158 0.158 0.309 0.309 0.115 0.408 0.001 0.0 0.487 0.082 0.082 - 0.0 0.0 0.045 0.045 0.0 - 0.054 - 0.09 - - - -

Capex To Depreciation

1.48 1.48 5.19 5.19 1.48 1.48 2.03 2.03 2.83 2.83 3.22 2.24 1.46 1.46 - 0.923 - 1.39 - 5.71 0.259 0.259 12.3 12.3 3.61 3.61 0.783 5.56 216 1.56 9.89 0.871 2 - 0.924 0.924 0.536 0.536 2.07 - 0.685 - 1.56 - - - -

Stock Based Compensation To Revenue

0.001 0.001 0.001 0.001 0.001 0.001 0.002 0.002 0.016 0.016 - 0.018 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Graham Number

0.009 0.009 0.012 0.012 0.005 0.005 0.003 0.003 0.003 0.003 0.103 0.002 0.163 0.003 0.152 0.0 0.103 0.006 191 0.003 0.004 0.004 0.002 0.002 0.003 0.003 4.13 3.65 0.003 0.003 1.97 5.17 - 2.86 0.006 0.006 0.003 0.003 0.006 0.006 0.005 13.2 0.004 0.006 - 7.88 -

Return On Invested Capital, ROIC

0.038 0.038 0.036 0.036 0.022 0.022 0.752 0.752 0.021 0.021 19.8 0.019 40.9 -5.18 53.4 0.023 31.3 -7.58 105 -14.8 0.034 0.034 0.107 0.107 0.598 0.598 -0.01 0.01 -0.033 -0.056 -0.043 -0.076 -0.118 0.008 -0.078 -0.078 -0.013 -0.013 -0.038 -0.038 -0.008 0.003 0.0 0.0 - 0.044 -

Return On Tangible Assets, ROTA

0.018 0.018 0.029 0.029 0.01 0.007 0.008 0.006 0.011 0.008 9.01 -0.003 27.8 0.007 26.6 0.0 10.1 0.025 94.2 0.013 0.027 0.02 -0.042 -0.034 0.022 0.019 -0.088 0.026 -0.024 -0.019 -0.006 -0.043 -0.079 -0.009 -0.043 -0.042 0.01 0.01 -0.03 -0.03 0.021 0.045 -0.018 -0.012 - 0.02 -

Graham Net Net

-0.013 -0.013 -0.011 -0.011 -0.014 -0.013 -0.012 -0.012 -0.012 -0.012 -0.012 -0.011 -0.011 -0.011 -0.012 -0.011 -0.011 -0.01 -10 -0.01 -0.012 -0.012 -0.01 -0.009 -0.009 -0.008 -9.79 -7.99 -0.008 -0.005 -5.21 -4.42 - -3.82 -0.003 -0.003 -0.002 -0.002 -0.002 -0.002 -0.002 -2.55 -0.003 -0.003 - -3.35 -

Working Capital

476 M 476 M 556 M 556 M 497 M 497 M 294 M 294 M 289 M 289 M 286 M 286 M 128 M 128 M 19.8 M 19.8 M 190 M 190 M 22.2 M 22.2 M 90.7 M 90.7 M 61 M 61 M -115 M -115 M -165 M -30.1 M -26.9 M 135 M 84.5 M 112 M -126 M -126 M -57.5 M -57.5 M -17.1 M -17.1 M -38.4 M -38.4 M -20.4 M -50.2 M -110 M -61.3 M 7.96 M -48.7 M -25.3 M

Tangible Asset Value

787 M 787 M 800 M 800 M 69.1 M 654 M -166 M 420 M -90.8 M 362 M -82.1 M 332 M -40.6 M 333 M -44 M 298 M 36 M 367 M -49.1 M 244 M -216 M 103 M -195 M -11.4 M -156 M -36.6 M 20.7 M 134 M 114 M 151 M 179 M 228 M 251 M 306 M 312 M 345 M 384 M 414 M 400 M 400 M 410 M 801 M 346 M 773 M 755 M 711 M 663 M

Net Current Asset Value, NCAV

-539 M -539 M -452 M -452 M -591 M -591 M -785 M -785 M -681 M -681 M -619 M -619 M -518 M -518 M -521 M -521 M -449 M -449 M -519 M -519 M -666 M -666 M -529 M -529 M -457 M -457 M -531 M -408 M -428 M -274 M -239 M -215 M -161 M -175 M -112 M -112 M -63.9 M -63.9 M -56.9 M -56.9 M -62.2 M -104 M -150 M -108 M -163 M -115 M -62.7 M

Invested Capital

1.01 B 1.01 B 1.05 B 1.05 B 1.54 B 957 M 1.31 B 725 M 1.14 B 687 M 1.11 B 699 M 925 M 551 M 809 M 467 M 999 M 668 M 821 M 528 M 962 M 644 M 654 M 471 M 506 M 386 M 226 M 326 M 325 M 351 M 297 M 225 M 15.9 M 11.5 M 86.8 M 53.9 M 134 M 104 M 93.8 M 93.8 M 106 M 61.7 M 23.7 M 59 M 214 M 73.5 M 33.5 M

Average Receivables

86 M 83.9 M 81.8 M 40.9 M 52 M 52 M 33.9 M 33.9 M 33.3 M 74.8 M 83.1 M 90.6 M 97.8 M 48.8 M 45.1 M 45.1 M 27 M 27 M 30.9 M 30.9 M 24.6 M 24.6 M 21.9 M 21.9 M 24.8 M 24.8 M - - 34.2 M 34.2 M 15.9 M 15.9 M - - 11.8 M 11.8 M 12.9 M 22.4 M 18.9 M 9.45 M - 27.9 M 27.9 M - - - -

Average Payables

28 M 40.7 M 53.4 M 100 M 89.7 M 49.8 M 50.4 M 72.5 M 82.9 M 78.5 M 69.1 M 62.8 M 89.8 M 93.6 M 66.4 M 69.8 M 68.1 M 57.4 M 61.9 M 57 M 73 M 97.2 M 101 M 82.6 M 78.1 M 71.8 M 64.9 M 78.7 M 91.6 M 85.3 M 59.1 M 41.5 M 35.2 M 18.6 M 17.4 M 13.1 M 8.04 M 4.67 M 3.97 M 11.2 M 133 M 127 M 99.3 M 98.6 M 93.2 M - -

Average Inventory

252 M 239 M 226 M 222 M 218 M 221 M 224 M 226 M 227 M 237 M 246 M 250 M 253 M 244 M 234 M 251 M 269 M 221 M 173 M 163 M 153 M 145 M 138 M 122 M 105 M 115 M 98.3 M 70.6 M 65.6 M 63.4 M 53.1 M 52.3 M 31.3 M 26 M 52.1 M 53.4 M 54.6 M 52.8 M 50.9 M 32.8 M 13.3 M 13.6 M 15.5 M 17.8 M 17.9 M - -

Days Sales Outstanding

20.8 20.8 19.7 19.7 - 30.1 - 19.8 - 23 0.012 24 0.016 31.6 - 25.7 - 21.5 - 24.7 - 23 - 22.4 - 30.4 - - - 0.053 - 34.6 - - - 0.027 - 30.7 0.018 0.018 - - 49.2 - - - -

Days Payables Outstanding

27.1 27.1 40.4 40.4 161 36 45.5 23.1 104 51 0.021 27 0.02 73 0.022 19.7 0.02 87.2 0.029 59.3 168 168 419 276 215 179 164 408 291 188 397 124 110 128 47.6 38 40.7 20.4 14.2 14.2 92.8 315 40.2 1.29 K - 384 -

Days Of Inventory On Hand

244 244 171 171 239 239 153 153 212 212 0.05 184 0.056 206 0.052 130 0.051 731 0.061 250 352 352 476 476 265 265 279 520 198 142 291 170 131 - 129 129 207 207 182 182 74.2 15.3 101 107 - 34.3 -

Receivables Turnover

4.33 4.33 4.57 4.57 - 2.99 - 4.55 - 3.91 7.52 K 3.75 5.68 K 2.85 - 3.5 - 4.19 - 3.65 - 3.91 - 4.01 - 2.96 - - - 1.68 K - 2.6 - - - 3.37 K - 2.94 4.9 K 4.9 K - - 1.83 - - - -

Payables Turnover

3.32 3.32 2.23 2.23 0.56 2.5 1.98 3.9 0.868 1.77 4.29 K 3.34 4.5 K 1.23 4.15 K 4.56 4.58 K 1.03 3.1 K 1.52 0.537 0.537 0.215 0.327 0.419 0.504 0.549 0.221 0.309 0.479 0.227 0.724 0.82 0.704 1.89 2.37 2.21 4.42 6.34 6.34 0.97 0.286 2.24 0.07 - 0.235 -

Inventory Turnover

0.369 0.369 0.526 0.526 0.376 0.376 0.59 0.59 0.424 0.424 1.79 K 0.488 1.59 K 0.437 1.73 K 0.691 1.77 K 0.123 1.48 K 0.361 0.256 0.256 0.189 0.189 0.339 0.339 0.322 0.173 0.454 0.634 0.309 0.529 0.686 - 0.7 0.7 0.434 0.434 0.494 0.494 1.21 5.88 0.891 0.844 - 2.62 -

Return On Equity, ROE

0.096 0.096 0.137 0.137 0.042 0.042 0.031 0.031 0.045 0.045 45.9 -0.017 125 0.044 144 0.001 53.2 0.168 934 0.15 0.167 0.167 -1.25 -1.25 0.143 0.143 -1.62 0.185 -0.223 -0.148 -0.041 -0.261 -0.278 -0.026 -0.118 -0.118 0.023 0.023 -0.069 -0.069 0.037 0.067 -0.037 -0.017 - 0.029 -

Capex Per Share

0.0 0.0 0.001 0.001 0.0 0.0 0.0 0.0 0.001 0.001 1.95 0.001 0.735 0.0 - 0.0 - 0.0 - 0.001 0.0 0.0 0.0 0.0 0.001 0.001 0.217 0.682 0.002 0.0 0.683 0.091 - - 0.0 0.0 0.0 0.0 0.0 - 0.0 - 0.0 - - - -

All numbers in RUB currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Институт стволовых клеток человека ISKJ
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Институт стволовых клеток человека plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
FSD Pharma FSD Pharma
HUGE
- 5743.5 % $ 69.7 M canadaCanada
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Compugen Ltd. Compugen Ltd.
CGEN
$ 2.02 -0.98 % $ 189 M israelIsrael
Happiness Biotech Group Limited Happiness Biotech Group Limited
HAPP
- 1.35 % $ 17.8 M chinaChina
Coherus BioSciences Coherus BioSciences
CHRS
$ 1.42 - $ 166 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Deciphera Pharmaceuticals Deciphera Pharmaceuticals
DCPH
- - $ 2.18 B usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
ASLAN Pharmaceuticals Limited ASLAN Pharmaceuticals Limited
ASLN
- -14.27 % $ 1.7 M singaporeSingapore
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd.
BVXV
- 0.74 % $ 768 M israelIsrael
Abcam plc Abcam plc
ABCM
- - $ 4.9 B britainBritain
Galera Therapeutics Galera Therapeutics
GRTX
- -32.59 % $ 7.61 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Affimed N.V. Affimed N.V.
AFMD
- -34.95 % $ 21.5 M germanyGermany
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
$ 51.48 -0.23 % $ 4.63 B schweizSchweiz
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
Celyad Oncology SA Celyad Oncology SA
CYAD
- - $ 12.5 M belgiumBelgium
Berkeley Lights Berkeley Lights
BLI
- -7.31 % $ 87 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 29.6 3.64 % $ 1.97 B usaUSA
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
IMV IMV
IMV
- - $ 13.1 M canadaCanada
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Freeline Therapeutics Holdings plc Freeline Therapeutics Holdings plc
FRLN
- - $ 384 M britainBritain
Gracell Biotechnologies Gracell Biotechnologies
GRCL
- - $ 3.37 B chinaChina
Anika Therapeutics Anika Therapeutics
ANIK
$ 14.57 -0.21 % $ 209 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 2.91 -5.52 % $ 4.79 M israelIsrael
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 22.79 5.8 % $ 2.9 B usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA